Dr. John Cush RheumNow
1 year 5 months ago
Finish Birth Cohort followed since 1986, who were asymptomatic, found abnormal MRI knee findings, esp cartilage defects in the patellofemoral (56%) & tibiofemoral joints (25%) joints. Small/doubtful patellofemoral (52%) & tibiofemoral (17%) osteophytes seen. Most w/ High BMI. https://t.co/LHqmRHM5wF
Rates of carpal tunnel syndrome were significantly greater in patients later diagnosed with rheumatoid arthritis, according to a large, long-running observational study.
Dr. John Cush RheumNow
1 year 5 months ago
GLP-1 agonists effective in Rxing MASH - metabolic dysfunction-assoc steatohepatitis (AKA NAFLD, NASH). DBRPCT w/ 1100 pts (mean BMI 34-35). A good perspective article from Sensible Medicine. https://t.co/NeaX5qcnPA https://t.co/loRPcwv8B9 https://t.co/ul8ko9cU4K
Dr. John Cush RheumNow
1 year 5 months ago
TONIGHT! Tuesday Night Rheumatology returns this month with the launch of Lupus Unlocked, starting with a special Journal Club session.
Join authors Dr. Richard Furie and Dr. Brad Rovin as they walk us through their pivotal studies on lupus nephritis:
📄 Obinutuzumab in Active https://t.co/REJQzVaslb
I think we're all somewhat familiar with PJP prophylaxis. This is the thing we do to stop the scary, opportunistic infection that affects people who are immunocompromised. I'm going to start by actually steelmanning the case for doing PJP prophylaxis before I explain why I think you probably shouldn't be doing too much of it.
Dr. John Cush RheumNow
1 year 5 months ago
Retrospective Medicare Claims data study of RA pts w/ metastatic non-small cell lung cancer who recv Rx w/ immune checkpoint inhibitor; found that ICI- Rx RA had the same survival as non-RA pts, and sterid use was not associated with worse survival https://t.co/JLlCfrRwvN https://t.co/DNEM32yocL
Dr. John Cush RheumNow
1 year 5 months ago
FDA has approved nipocalimab (Imaavytm), a FcRn for use in generalized myasthenia gravis (gMG). It is approved for using in gMG patents who are anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. https://t.co/fYCWuTZ6Uz https://t.co/aSfydBS9xh
Dr. John Cush RheumNow
1 year 5 months ago
67 systemic sclerosis pts w/ mod-to-severe lower GI Sxs were Rx in phase 2, RDBPCT of placebo or fecal transplants at wks 0 and 2, with no signif change in GI sxs by week 12 (bloating or diarrhoea). https://t.co/vWq2c8d4Kn https://t.co/PpPsAQbj5M
Dr. John Cush RheumNow
1 year 5 months ago
Triple positivity (anti-CarP Abs, RF, ACPA) assoc w/ increased Dz activity in RA. Single center, 138 RA pts. Triple pos. pts had signif more TJC (10 v 7.7), Pain (6.3 v 5.1), DAS28-CRP (4.7 vs. 4.0), ESR (33 v 23), ACPA (395 v 369), but lower RF (164 v 453). NO diff in Bone https://t.co/DexENW4W2T
Dr. John Cush RheumNow
1 year 5 months ago
D-Lay MS trial: DBRPCT of Oral cholecalciferol 100 000 IU q2wks x 24 mos.signif reduced Dz activity in clinically isolated syndr(CIS) & early relapsing-remitting MS typical for MS. Dz activity seen in 60% w/ Vit D vs 74% w/ PBO (HR 0.66). Also time to Dz activity (432 vs 224d; https://t.co/GQsnnuWS9R
An open-label, single-centre, randomized controlled trial tested whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in systemic lupus erythematosus (SLE) patients and found that IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term clinical remission.
Dr. John Cush RheumNow
1 year 5 months ago
Very low & very high vitamin D (25/OH) levels assoc w/ adverse pregnancy outcomes - miscarriage (P = 0.0045) & preterm delivery (P = 0.0007). APO were lowest w/ 25(OH)D levels of 40 to 59 ng/mL. Monitor vit D and Rx during SLE pregnancies https://t.co/Z9jEgETqId https://t.co/fJRqD3v7UF
